An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer

This open-label, randomized, phase II study was intended to compare paclitaxel-carboplatin plus necitumumab versus paclitaxel-carboplatin alone for the first-line treatment of advanced squamous non-small cell lung cancer. Addition of necitumumab to chemotherapy resulted in an objective response rate of 48.9% versus 40.0% for chemotherapy alone. There were no unexpected safety concerns for an epidermal growth factor receptor monoclonal antibody.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2mbvVjZ
via IFTTT